Effect of oxalipatin combined with S-1 on related protein expression in advanced gastric cancer / 中国基层医药

ABSTRACT

Objective To analyze the clinical effect of neoadjuvant chemotherapy( oxaliplatin combined with S-1) in the treatment of advanced gastric cancer,and to detect its influence on expressions of vascular endothelial growth factor(VEGF) and matrix metalloproteinase-2(MMP-2).Methods A total of 70 patients with advanced gastric cancer were randomly divided into research group ( n=35 ) and control group ( n=35 ) .The patients in the control group were given surgery treatment and general drug chemotherapy,while the patients in the research group were given the neoadjuvant chemotherapy on the basis of the control group.The incidence of cancer recurrence and the expressions of MMP-2,VEGF of the two groups were observed.Results In the research group,the expressions of MMP-2 or VEGF were significantly different before and after chemotherapy(χ2 =10.03,χ2 =9.11,all P<0.01). The 3-year survival rate in the research group(71.43%) was significantly higher than 45.71% in the control group,there was significant difference(χ2 =11.70,P<0.05).Conclusion Neoadjuvant chemotherapy can reduce the expressions of MMP-2 and VEGF in tumor tissues,indicates that it may play an important role in patients with advanced gastric cancer and can be used in clinic.